Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038458 | 0.89 | LMNA (0.34) | ESR1ESR2AKT1HPGDALDH1A1 | |
| SCHEMBL3603597 | 0.84 | MAPT (0.33) | ALDH1A1ABCB1MAPTTP53SMN1; SMN2 | |
| SCHEMBL3596490 | 0.83 | MAPT (0.37) | AKT1ALDH1A1ABCB1MAPTTP53 | |
| SCHEMBL3592061 | 0.83 | HTR2B (0.33) | ALDH1A1ABCB1MAPTTP53SMN1; SMN2 | |
| SCHEMBL3592483 | 0.80 | ABCB1 (0.38) | HPGDALDH1A1ABCB1MAPTTP53 | |
| SCHEMBL2912988 | 0.75 | AR (0.41) | — | |
| SCHEMBL3609026 | 0.75 | ALDH1A1 (0.40) | HPGDALDH1A1MAPTTP53SMN1; SMN2 | |
| SCHEMBL3602995 | 0.74 | HPGD (0.39) | HPGDALDH1A1ABCB1MAPTTP53 | |
| SCHEMBL3599011 | 0.74 | ABCB1 (0.41) | ALDH1A1ABCB1MAPTTP53SMN1; SMN2 | |
| SCHEMBL3608081 | 0.73 | ABCB1 (0.33) | ABCB1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1323716-B1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | TAKEDA PHARMACEUTICAL (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| US-7008950-B1 | Benzofurans as suppressors of neurodegeneration | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1323716-A1 | PROMOTERS FOR THE PROLIFERATION AND DIFFERENTIATION OF STEM CELLS AND/OR NEURON PRECURSOR CELLS | Takeda Chemical Industries, Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012081-A1 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells | NES, MKI67, CCNO | ESR1 2400/4885ESR2 994/4885AKT1 493/4885 |
| US-20040034049-A1 | Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells | NES, HAT1, PROX1 | ESR1 2474/4885ESR2 1088/4885AKT1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.